What’s the current market cap for Lexicon Pharmaceuticals stock?

Lexicon Pharmaceuticals (LXRX) has a market cap of $871m as of June 16, 2026.

What is the P/E ratio for Lexicon Pharmaceuticals stock?

The price to earnings (P/E) ratio for Lexicon Pharmaceuticals (LXRX) stock is 0 as of June 16, 2026.

Does Lexicon Pharmaceuticals stock pay dividends?

No, Lexicon Pharmaceuticals (LXRX) stock does not pay dividends to its shareholders as of June 16, 2026.

When is the next Lexicon Pharmaceuticals dividend payment date?

Lexicon Pharmaceuticals (LXRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (LXRX) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Lexicon Pharmaceuticals stock | $LXRX Share Price

13:30

15:10

16:45

18:25

20:00

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Ticker

$LXRX

Sector

Health

Primary listing

NASDAQ

Employees

Headquarters

The Woodlands, United States

Website

www.lexpharma.com

LXRX Metrics

BasicAdvanced

$871m

-$0.07

0.97

What the Analysts think about LXRX

Analyst ratings (Buy, Hold, Sell) for Lexicon Pharmaceuticals stock.

Bulls say / Bears say

In March 2026, Novo Nordisk initiated a Phase 1 clinical trial of Lexicon’s LX9851 obesity candidate, triggering a second $10 million milestone payment and highlighting strong partner validation of its cardiometabolic pipeline (© Thomson Reuters) (TradingView)

Q1 2026 net loss narrowed dramatically to $1.0 million from $25.3 million in Q1 2025, driven by a $20 million milestone payment from Novo Nordisk, demonstrating effective monetization of licensing partnerships (Investing.com)

Lexicon remains on track for mid-2026 NDA resubmission and potential U.S. approval of Zynquista (sotagliflozin) as an adjunct therapy for type 1 diabetes, contingent on positive data from the investigator-initiated STENO1 study, setting a near-term regulatory catalyst (Lexicon press release and AdvFN))

As of November 6, 2025, Lexicon’s at-the-market equity program of up to $75 million has produced no share sales, suggesting limited investor appetite for its new equity offerings (StockTitan)

In Q1 2026, milestone revenue of $20 million accounted for roughly 95% of total $21.1 million revenues, with net product sales only $1.09 million, exposing the company to concentrated revenue risk (Lexicon Form 10-Q)

Lexicon incurred $11.4 million in R&D and $6.4 million in general and administrative expenses in Q1 2026, totaling $22.1 million in operating costs and underscoring continued cash burn ahead of product commercialization (Lexicon Form 10-Q)

Data summarised monthly by Lightyear AI. Last updated on 15 Jun 2026.

LXRX Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

LXRX Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $LXRX

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

As of November 6, 2025, Lexicon’s at-the-market equity program of up to $75 million has produced no share sales, suggesting limited investor appetite for its new equity offerings (StockTitan)

Data summarised monthly by Lightyear AI. Last updated on 15 Jun 2026.